A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia, according to new findings.
from Top Health News -- ScienceDaily https://ift.tt/2qAwODq
No comments:
Post a Comment